Golidocitinib favorable for relapsed/refractory T-cell lymphoma

Cancer. 2024 Apr 15;130(8):1191-1192. doi: 10.1002/cncr.35272.
No abstract available

Publication types

  • News

MeSH terms

  • Humans
  • Lymphoma, T-Cell* / drug therapy
  • Neoplasm Recurrence, Local* / drug therapy